Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00030264 Phase II Vinblastine Methotrexate Combination Chemotherapy in Treating Patients With Neurofibromatosis and Progressive Plexiform Neurofibromas Completed USA 0
NCT01362803 Phase Ib/II Selumetinib AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors Active, not recruiting USA 0
NCT02101736 Phase II Cabozantinib Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 (16 Years +) Completed USA 0
NCT02124772 Phase I Trametinib Dabrafenib + Trametinib Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations Completed USA | GBR | FRA | CAN | AUS 0
NCT02390752 Phase Ib/II Pexidartinib PLX3397 in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Recruiting USA 0
NCT02407405 Phase II Selumetinib MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas Active, not recruiting USA 0
NCT02639546 Phase Ib/II Cobimetinib Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors (iMATRIXcobi) Completed USA | ITA | GBR | FRA | ESP | DEU 1
NCT03231306 Phase II Binimetinib Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas (NF108-BINI) Active, not recruiting USA 0
NCT03326388 Phase Ib/II Selumetinib Intermittent Dosing Of Selumetinib In Childhood NF1 Associated Tumours (INSPECT) Completed GBR 0
NCT03363217 Phase Ib/II Trametinib Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway. Active, not recruiting CAN 0
NCT03688568 Phase II Imatinib Study of Imatinib in Children With Neurofibromatosis and Airway Tumors Withdrawn USA 0
NCT03962543 Phase II PD-0325901 MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas (ReNeu) Active, not recruiting USA 0
NCT04465643 Phase I Ipilimumab + Nivolumab Neoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral Nerve Sheath Tumor Recruiting USA 0
NCT04750928 Phase Ib/II Abemaciclib Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas Recruiting USA 0
NCT04924608 Phase III Selumetinib Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas (KOMET) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS 5
NCT04954001 Phase Ib/II FCN-159 Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1 Active, not recruiting USA | ESP 1
NCT05101148 Phase I Selumetinib Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Toxicity of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas Active, not recruiting USA | ESP 2
NCT05309668 Phase Ib/II Selumetinib Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children Aged >/=1 to <7 Years With NF1-related Symptomatic, Inoperable PN (SPRINKLE) Recruiting USA | NLD | ITA | ESP | DEU 2